Nobuo Shinohara

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Medicine, Oncology, Pharmacology +16

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial

Takeshi Ueda, Hirotsugu Uemura, Y. Tomita et al. · Japanese Journal of Clinical Oncology · 2013 · 71 citations · Full text

Medicine, Oncology, Pharmacology +14

Chromophobe renal cell carcinoma, oncocytic variant: a proposal of a new variant giving a critical diagnostic pitfall in diagnosing renal oncocytic tumors

Naoto Kuroda, Azusa Tanaka, Tadanori Yamaguchi et al. · Medical Molecular Morphology · 2013 · 45 citations

Medicine, Oncology, Pathology +14

Clinical outcome of tumor recurrence for Ta, T1 non‐muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999–2001 report from the Japanese Urological Association

Eiji Kikuchi, Hiroyuki Fujimoto, Yoichi Mizutani et al. · International Journal of Urology · 2009 · 44 citations

Medicine, Surgery, Urology +12